Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Metabolic syndrome.

C Vitale1, G Marazzi, M Volterrani

  • 1Department of Medical Sciences, IRCCS San Raffaele, Rome, Italy. cristiana.vitale@sanraffaele.it

Minerva Medica
|July 21, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First Search for B→X_{s}νν[over ¯] Decays.

Physical review letters·2026
Same author

Search for Feebly Interacting Particles in B Decays with Missing Energy at Belle.

Physical review letters·2026
Same author

Evidence for the Collective Nature of Radial Flow in Pb+Pb Collisions with the ATLAS Detector.

Physical review letters·2026
Same author

Evidence for the Dimuon Decay of the Higgs Boson in pp Collisions with the ATLAS Detector.

Physical review letters·2025
Same author

Search for B^{0}→K^{*0}τ^{+}τ^{-} Decays at the Belle II Experiment.

Physical review letters·2025
Same author

Search for a Dark Higgs Boson Produced in Association with Inelastic Dark Matter at the Belle II Experiment.

Physical review letters·2025
Same journal

How to become a centenarian in four weeks?. Myths and limits of longevity recipes: a critical review.

Minerva medica·2026
Same journal

Comparative efficacy and safety between intravenous recombinant human prourokinase and alteplase in acute ischemic stroke treatment: a meta-analysis of randomized controlled trials.

Minerva medica·2026
Same journal

Efficacy and safety of oral tapentadol for cancer-related pain: an updated systematic review and meta-analysis.

Minerva medica·2026
Same journal

Use of the neurostimulator in thyroidectomy procedures: comparison between vagal and recurrent laryngeal nerve stimulation.

Minerva medica·2026
Same journal

Iron deficiency and risk of acute kidney injury after TAVI: a machine learning analysis.

Minerva medica·2026
Same journal

Therapeutic adherence and health literacy: a perfect match in dyslipidemic patients.

Minerva medica·2026
See all related articles

Metabolic syndrome (MS) involves clustered cardiovascular risks, increasing atherosclerosis and type 2 diabetes risk. Managing MS focuses on reducing cardiovascular events and preventing diabetes through lifestyle changes and specific medications.

Area of Science:

  • Cardiology
  • Endocrinology
  • Metabolic Disorders

Background:

  • Cardiovascular risk factors often cluster, defining metabolic syndrome (MS).
  • MS significantly elevates risks for atherosclerosis, cardiovascular events, and type 2 diabetes.
  • Its epidemic nature makes it a major challenge in cardiovascular disease management.

Purpose of the Study:

  • To outline the key components and risks associated with metabolic syndrome.
  • To emphasize therapeutic goals in managing MS patients, including risk reduction for cardiovascular events and diabetes.
  • To highlight the importance of lifestyle modifications and pharmacological interventions.

Main Methods:

  • Review of existing evidence on metabolic syndrome.
  • Analysis of risk factors including insulin resistance, obesity, dyslipidemia, and hypertension.

Related Experiment Videos

  • Evaluation of therapeutic strategies, including lifestyle changes and medications like Metformin and Acarbose.

    • Main Results:

    • Metabolic syndrome encompasses insulin resistance, abdominal obesity, dyslipidemia, hypertension, and prothrombotic/proinflammatory states.
    • Effective management aims to reduce cardiovascular events and prevent type 2 diabetes.
    • Lifestyle changes and specific drugs (Metformin, Acarbose) show efficacy in reducing events and mortality.

    Conclusions:

    • Intensified risk factor management is crucial for patients with MS, especially those with diabetes.
    • Lifestyle interventions are fundamental for managing predisposing factors like obesity and inactivity.
    • Certain antihypertensive drug classes require careful consideration due to metabolic profiles in MS patients.